Tagged with Brexit,

UK Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with developing Alzheimer’s products at a time when many MNCs are winding down their neurology programs. How would you describe Biogen’s…

UK Tony Jones, CEO of One Nucleus, a life sciences membership organization centered on the Greater London-Cambridge-East of England corridor, discusses the role of SMEs within the UK’s healthcare ecosystem, translational research, and how the association’s members will navigate the post-Brexit landscape in the UK.  One Nucleus, which was established in…

UK Lord O’Shaughnessy, parliamentary under secretary of state for health in the UK, discusses how stakeholders are interacting to ensure that the UK remains at the forefront of the global life sciences industry post-Brexit.    We have scrutinized the Life Sciences Industrial Strategy and found it to be a very optimistic…

UK Mike Belton of the British Swiss Chamber of Commerce discusses the capabilities of the organization, its role within the British and Swiss investment ecosystem, and how Switzerland can act as a model for the UK post-Brexit. Can you start by introducing the British Swiss Chamber of Commerce so we can…

UK Lord Philip Hunt, a former UK health minister during the Blair and Brown governments, shares his thoughts on procurement in healthcare, structural change and its impact, and how funds may present some solution to the problems the NHS is currently facing. In a career spanning over 30 years of service…

UK British consultant, speaker and author, Richard Barker – a key opinion leader on UK healthcare – gives his take on the recently launched ‘Life Sciences Industrial Strategy’, the importance of facilitating accelerated access to medicines, and the potential fallout from Brexit to the UK’s life sciences ecosystem.   On the…

UK Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits of inter-stakeholder collaboration. Entering 2018, three key themes affecting the British generics industry are Brexit, a new life science industry…

UK Simon Gillespie of the British Heart Foundation (BHF), the UK’s leading national heart charity, outlines the organization’s mission, the issues surrounding translational research, and the potential impact of Brexit on the UK life sciences landscape.   One of the key matters for us is that we don’t have direct customers.…

UK UK pharmaceutical and biotech companies are already finding it increasingly difficult to attract talent from overseas. Additionally, UK firms are looking to poach EMA staff as it heads to Amsterdam from London following Brexit. Following the Brexit vote, the UK is already seeing problems in filling senior positions at life…

EMA The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following three rounds of voting. “We are delighted, it was very tight, it was nerve-wracking, to be honest” Halbe Zijlstra, Minister…

UK Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving the European Atomic Energy Community (Euratom) on cancer care in the UK. “The UK relies on Euratom for the diagnosis…

Indonesia Chris Wren, Executive Director of BritCham for the last ten years, explains the changes that have happened on the Indonesian market as well as opportunities for foreign companies to invest more in the upcoming years. BritCham is one of the most dynamic international business chambers in Indonesia. Can you please…